Welcome to Pre-ASCO Corner

Looking for medical conference coverage?   We provide comprehensive analysis and insights. Reach us at info@raslss.com or +49-157-582-97742

From the Desk of our CEO

RAS Viewpoint

  • Journey through ASCO 2015 to 2017
    In ASCO 2017, it will be great to see the new treatment options i.e. IOs and their combinations paving their way in other tumors. It would be informative to see how the disease landscape has evolved with the advent of IOs in the last one year. Equally, it would be […]
  • Glioblastoma Multiforme Abstracts – RAS Viewpoint
    An aggressive malignancy, Glioblastoma is an indication with one of the highest level of unmet need in oncology. Currently, Avastin and Temozolomide dominates the market.  With GBM market estimated to reach $3.3B (G7 market) by 2024 (Globaldata), companies are trying out novel approaches. GBM pipeline is characterized by active early […]
  • Merck @ASCO 2017
    Merck will present data for KEYTRUDA® Across 16 Types of Cancer at the 2017 ASCO Annual Meeting Researchers will present data from more than 50 abstracts investigating the use of KEYTRUDA as monotherapy and in novel combinations across 16 cancers, including NSCLC, melanoma, urothelial carcinoma, microsatellite instability-high (MSI-H) cancers, gastric […]
  • Pfizer @ASCO 2017
    Pfizer will present more than 50 abstracts, involving more than 15 clinical-stage assets across solid and hematologic tumors and 12 moA, at the ASCO in Chicago from June 2-6, 2017. New data will be featured in 9 oral presentations from company-sponsored clinical trials, including a late-breaker on the investigational compound […]
  • Janssen @ASCO 2017
    Janssen will present new data for both approved and investigational oncology compounds at ASCO 2017 Annual Meeting. 19 company-sponsored abstracts have been accepted for presentation, including for abiraterone acetate, daratumumab and ibrutinib. Most notably, Phase 3 pivotal trial results for abiraterone acetate will be featured in the ASCO Press Briefing […]
  • Celgene @ASCO 2017
    Celgene will demonstrate its broad range of Oncology Clinical Development Program evaluating its investigational pipeline & marketed products at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. Presentations will include multiple solid tumor and blood cancers while highlighting the value of innovative […]
  • Digital Health Abstracts @ ASCO 2017
    The remote patient management or tele-healthcare as a concept is only starting to take off in Oncology. The readouts, though limited by their small sample size, have shown positive impact of technology on care providers, patient outcomes and the overall cost burden. Normally, larger studies would be needed to validate […]
  • BMS @ASCO 2017
    Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017 More than 80 presentations (including16 oral presentations and 7 poster discussions), highlighting data from Company-sponsored studies, collaborations and IS research spanning 20 types of cancer, with focus on research of precision therapies […]
  • AstraZeneca @ASCO 2017
    AstraZeneca (AZ), along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company’s science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. With three new oncology […]
  • Amgen @ASCO 2017
    Amgen announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2-6, 2017. Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic […]
  • AbbVie @ASCO 2017
    AbbVie will present a total of 23 abstracts across several tumor types including brain cancer, hematologic malignancies, breast cancer, lung cancer and other solid tumors. Researchers will present efficacy and safety data on depatuxizumab mafodotin, an antibody-drug conjugate (ADC) being studied for the treatment of adults with amplified EGFR newly […]
  • Liquid Biopsies in Cancer: Opportunities and Challenges
    Liquid Biopsy is a term given to a minimally invasive method of analyzing Tumor cell DNA circulating in the blood. This is a useful and very promising approach and opens new vistas compared to the Biochemical Biomarkers and Tissue Biopsies dependent monitoring of cancer. However, it throws its own challenges […]
  • CRC Abstracts – RAS Viewpoint
    At ASCO 2017, the steadily increasing competitive intensity between Lonsurf (TAS-102, Taiho) and Stivarga (regorafenib, Bayer) will be on display . In addition, the I/O agents are reading out both as monotherapy in specific (dMMR/MSI-H) patient segments, as well as in combinations with other cytotoxic and targeted agents in broader patient […]
  • Prostate Cancer Abstracts – RAS Viewpoint
    ASCO 2017 is primarily setting the stage for future as it relates to Prostate Cancer – a large number of presentations are focused on early stage data from new compounds and/or combinations of existing. The truly practice impacting trials such as IMbassador250, ARASENS, PROfound and TRITON3 will be touched upon […]
  • Biomarkers in Colorectal Cancer
    Colorectal Cancer Diagnostics and monitoring CRC diagnostics and monitoring follows two pronged strategy Diagnostic tools such as Colonoscopy: Specific, Can Remove Polyps and Take Biopsies. Adverse: Can cause perforation, Can miss small adenomas Flexible sigmoidoscopy: Specific, Can Remove Polyps and Take Biopsies. Adverse: Reduced risk of perforation Double-contrast barium enema: […]
  • Future of Cancer Care 2030 – RAS Viewpoint
    There are four areas of innovation that are noticeable both in isolation and how they feed into each other for a transformation in cancer care “Big data” and Bioinformatics – rapidly developing data management systems and analytics e.g. NGS that will enable us to collect, analyze and learn from vast amounts […]
  • Biosimilars ASCO 2016
    Biosimilars at ASCO 2016
    Mylan’s Phase 3 clinical read out was the biosimilar show stopper at ASCO 2016. The biosimilar awareness amongst the attendees was reflected by the full house attendance of biosimilar sessions and presentations throughout the conference. The clinical data from the Phase 3 HERiTAge study, comparing Mylan’s MYL-1401O, potential trastuzumab biosimilar […]
  • Biosimilars ASCO 2015
    Biosimilars at ASCO 2015
    The year 2015 marked the approval of the first biosimilar via the BPCIA pathway in USA. The murmurs of biosimilars could be heard in the corridors of ASCO-2015. A total of 3 clinical read-outs and industry sponsored activities marked the largest oncology congregation of 2015. Russia-based biosimilar developer, Biocad presented […]

ASCO 2017 - At a Glance: Pre-ASCO Analytics

Key Sessions Schedule

 
[Spider_Calendar id="1" theme="13" default="month" select="month,list,week,day,"]

Link to ASCO Company Booths and Floor Plans

 

@ASCO 2016 Booth Coverage Sampler

RAS LSSRAS LSSRAS LSSRAS LSSRAS LSSRAS LSSRAS LSSRAS LSSRAS LSSRAS LSSRAS LSSRAS LSSRAS LSSRAS LSSRAS LSSRAS LSS